NewsBenzingaBMO Capital mantiene il rating Outperform su Strategic Education, abbassa il target di prezzo a $95 BMO Capital mantiene il rating Outperform su Strategic Education, abbassa il target di prezzo a $95 Benzinga 2026.10.05 18:18 (GMT+0) Open on Benzinga Other news F&G Annuities & Life Estimates Q3 2026 Investment Income From Alternative Investments At $47M-$57M Pre-Tax; Estimated Investment Income From Alternative Investments $70M Pre-Tax, $55M Post-Tax Below Expected Return Guggenheim Initiates Coverage On Ovid Therapeutics with Buy Rating, Announces Price Target of $7 $1000 Invested In Twist Bioscience 5 Years Ago Would Be Worth This Much Today Vir Biotechnology To Reveal Expanded Phase 2 SOLSTICE Results for Elebsiran And Tobevibart In Hepatitis Delta at AASLD’s The Liver Meeting 2026 Aviat Networks Announces License-To-Manufacture Agreement With Dixon Electro Appliances For Designated Products In Aviat's WTM 4000 Family In India UBS Maintains Buy on Ashland, Lowers Price Target to $80
F&G Annuities & Life Estimates Q3 2026 Investment Income From Alternative Investments At $47M-$57M Pre-Tax; Estimated Investment Income From Alternative Investments $70M Pre-Tax, $55M Post-Tax Below Expected Return
Vir Biotechnology To Reveal Expanded Phase 2 SOLSTICE Results for Elebsiran And Tobevibart In Hepatitis Delta at AASLD’s The Liver Meeting 2026
Aviat Networks Announces License-To-Manufacture Agreement With Dixon Electro Appliances For Designated Products In Aviat's WTM 4000 Family In India
